iShares US Pharmaceuticals ETF
82 hedge funds and large institutions have $147M invested in iShares US Pharmaceuticals ETF in 2019 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 17 increasing their positions, 34 reducing their positions, and 13 closing their positions.
37.62% more ownership
Funds ownership: 102.5% → 140.12% (+38%)
33% more capital invested
Capital invested by funds: $111M → $147M (+$36.3M)
6% less funds holding
Funds holding: 87 → 82 (-5)
31% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 13
50% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 34
100% less call options, than puts
Call options by funds: $1K | Put options by funds: $348K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$57.5M |
| 2 |
RCYC
Richard C. Young & Co
Newport,
Rhode Island
|
+$3.92M |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$3.47M |
| 4 |
Fisher Asset Management
Camas,
Washington
|
+$222K |
| 5 |
Wolverine Trading
Chicago,
Illinois
|
+$221K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$6.2M |
| 2 |
BW
Biegel & Waller
Columbia,
Maryland
|
-$5.99M |
| 3 |
Morgan Stanley
New York
|
-$1.61M |
| 4 |
Wells Fargo
San Francisco,
California
|
-$1.05M |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1.01M |
IHE Hedge Fund Activity: Q3 2019 in Review
82 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in iShares US Pharmaceuticals ETF (IHE) for Q3 2019, worth a combined $147M — up 33% from $111M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of IHE and 9 opened new positions — a net loss of 4 holders — while 34 trimmed existing stakes and 17 added.
The largest buyer was Goldman Sachs, adding an estimated $57.5M. The largest seller was Jane Street, cutting an estimated $6.2M.
- 82 institutional investors held iShares US Pharmaceuticals ETF (IHE) as of Q3 2019, down from 87 in Q2 2019.
- Funds reported $147M of iShares US Pharmaceuticals ETF stock for Q3 2019, up 33% quarter-over-quarter.
- 9 funds opened new iShares US Pharmaceuticals ETF positions in Q3 2019 and 13 closed out, a net change of -4 holders.
- The largest iShares US Pharmaceuticals ETF buyer in Q3 2019 was Goldman Sachs, an estimated $57.5M added.
- The largest iShares US Pharmaceuticals ETF seller in Q3 2019 was Jane Street, an estimated $6.2M sold.
Based on aggregated 13F filings for Q3 2019.